Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Summary

This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.

Timeline

Start

2024-06-01

Primary completion

2026-06-30

Completion

2026-12-31

Drugs

Indications